• Corpus ID: 18874267

In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.

  title={In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.},
  author={David L. Emerson and Jeffrey M. Besterman and Hannnah Brown and Michael G. Evans and Peter Leitner and Michael Joseph Luzzio and J E Shaffer and Daniel D. Sternbach and David E Uehling and A Vuong},
  journal={Cancer research},
  volume={55 3},
The development of camptothecin-like compounds as inhibitors of topoisomerase I for the treatment of resistant tumors has generated clinical excitement in this new class of drugs. We have developed two novel water-soluble camptothecin analogues which are specific inhibitors of topoisomerase I and are potent cytotoxins with significant antitumor activity. We added water-solubilizing groups off position 7 in the B ring of either 10,11-ethylenedioxy- or 10,11-methylenedioxy-20(S)-camptothecin… 

Figures and Tables from this paper

Topoisomerase I Inhibition by the Camptothecin Analog G1147211C

In vivo preclinical antitumor activity of Gl147211C was compared to topotecan in an array of human tumor xenograft models in nude mice, and microscopic evaluation of necropsied tissues indicated that drug-induced toxicity was mild, primarily limited to the gastrointestinal tract, and was comparable for both Gl14 7211C and topotECan.

Modulation of camptothecin analogs in the treatment of cancer: a review

Preclinical and clinical data is presented on CPT analogs that are already being used in clinical practice, or are currently in clinical development, as well as drugs that are still only developed in a preclinical setting.

Topoisomerase I inhibitors: review and update.

  • M. Rothenberg
  • Biology, Chemistry
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1997
The challenge for the next five years is to identify ways to integrate the topo I inhibitors into multidrug and multimodality therapies to achieve optimal antitumour effect, while keeping the side effects of these therapies manageable.

Camptothecins: a review of their chemotherapeutic potential.

Camptothecin analogues and derivatives appear to exert their antitumour activity by binding to topoisomerase I and have shown significant activity against a broad range of tumours. In general,

Current perspectives on camptothecins in cancer treatment.

The unfolding story of camptothecin analogue development will give important insights into the predictive value of preclinical observations on relative efficacy, schedule dependency, combination strategies and resistance mechanisms which have helped determine the strategies for clinical evaluation of these agents.

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

  • W. LoosJ. Verweij A. Sparreboom
  • Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
It was found that MEC was the product of rapid photolysis of lurtotecan, with the rate of degradation inversely proportional to NX 211 concentrations, and greatly depends on light intensity, and procedures to minimize formation of MEC are now being routinely implemented.

Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.

The results indicate that water-soluble 20(S)-glycinate esters of highly potent CPT analogues provide compounds that maintain biological activity, do not require interactions with carboxylesterases, and do not inhibit human acetylcholinesterase.

Recent developments in the clinical activity of topoisomerase-1 inhibitors.

Clinical studies of camptothecin and derivatives.




Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.

A large number of camptothecin analogs have been prepared in the 20S, 20RS, and 20R configurations with a number of ring A substituents, and the activities of some of the analogs as determined in a variety of in vivo assays were, in general, in accord with T-I inhibition.

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

Stereochemistry and the positions of substituents were found to be crucial for the presence or absence of effects on topoisomerase I, indicating that the compounds interact with an asymmetrical receptor site on the enzyme or enzyme-DNA complex.

Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.

It was found that monosubstitution by NH2 or OH at positions 9, 10, or 11 yielded compounds with activity much higher than the parent compound, camptothecin, whereas substitution at position 12 greatly reduced activity, which greatly reduced antileukemic activity.

Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

This schedule appears to allow a CPT-11 dose intensity which is double the dose intensity possible on a once-a-month schedule, however, careful supervision to assess gastrointestinal toxic effects and myelosuppression is indispensable because of wide individual differences in drug tolerance.

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

  • M. FukuokaH. Niitani N. Masuda
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
CPT-11 is a very active agent for NSCLC with acceptable toxicities and further trials in combination with other agents for this disease are warranted.

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

It is suggested that P-glycoprotein overexpression diminishes TPT accumulation and TPT cytotoxicity in hamster and human cells.

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Neutropenia is the dose-limiting toxicity, and 1.5 mg/m2 is the recommended starting dose of topotecan for both minimally and heavily pretreated patients in future phase II trials, with escalation to 2.0 mg/ m2 if treatment is well tolerated.

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

Unlike other anticancer drugs tested, 20(RS)-9-amino-camptothecin (9-AC) induced disease-free remissions and the overall drug toxicity was low and allowed for repeated courses of treatment.

Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

The recessive behavior of the CptR mutation provides a plausible explanation for the reduced topoisomerase I content (about one-half of wild-type cells) of the mutant cells and also for their enhanced sensitivity towards inhibitors of topoisomersase II.